Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide

Abbott

Status: Completed

Conditions: Irritable Bowel Syndrome

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT01678781

P13-678

Details and patient eligibility

About

A study to evaluate, by country and overall, the changes from baseline of the irritable bowel syndrome quality of life (IBS QoL) total score after 4 and 8 weeks of treatment with Duspatalin® or Dicetel® in IBS patients.

Enrollment: 607 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Irritable bowel syndrome patients diagnosed by Rome III criteria (18 years or older)

Exclusion criteria

• Pregnancy and lactation
• Specific contraindications to mebeverine hydrochloride or pinaverium bromide

Trial design

607 participants in 1 patient group

One patient group

Description:

Patients suffering from irritable bowel syndrome